AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30951926 — intervention group
Group type: COMPARATOR
Intervention: Comparison of eligible non-participants
Number of subjects: 755
Study 30195616 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral regimen
Number of subjects: 601
Study 30195616 — intervention group
Group type: COMPARATOR
Intervention: No antiviral treatment
Number of subjects: 601
Study 26762481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 392
Study 26762481 — intervention group
Group type: COMPARATOR
Intervention: Heparin with or without tirofiban
Number of subjects: 392
Study 24170449 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior medical students
Number of subjects: 99
Study 24170449 — intervention group
Group type: COMPARATOR
Intervention: Junior doctors
Number of subjects: 99
Study 22340303 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photographs for diagnosing HOA
Number of subjects: 381
Study 22340303 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photographs for predicting pain on most days for at least a month in females
Number of subjects: 381
Study 22340303 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photographs for diagnosing intermittent pain in DIP and PIP joints
Number of subjects: 381
Study 22340303 — intervention group
Group type: COMPARATOR
Intervention: Radiography for predicting pain in CMC1 joints
Number of subjects: 381
Study 22340303 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination for predicting pain in CMC1 joints
Number of subjects: 381
Study 22340303 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photographs for diagnosing HOA using a shortened method
Number of subjects: 381
Study 20339369 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone plus mifepristone
Number of subjects: 76
Study 20339369 — intervention group
Group type: COMPARATOR
Intervention: risperidone plus placebo
Number of subjects: 76
Study 17385265 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (1 mg/kg) administered intravenously over 60 minutes
Number of subjects: 14
Study 17385265 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously over 60 minutes
Number of subjects: 14
Study 15718412 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (9 resistance exercises at 75% of 1 repetition maximum)
Number of subjects: 16
Study 15718412 — intervention group
Group type: COMPARATOR
Intervention: Sham control (seated rest in the exercise room)
Number of subjects: 16
Study 11978255 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once a day for 10 days
Number of subjects: 196
Study 11978255 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin 500 mg three times per day for 10 days
Number of subjects: 196
Study 9436066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 52
Study 9436066 — intervention group
Group type: COMPARATOR
Intervention: Postpartum
Number of subjects: 52
Study 7897786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention with increased intensity and frequency of visits (visits with primary care physician and psychiatrist) and continued surveillance of adherence to medication regimens.
Number of subjects: 217
Study 7897786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 217
Study 7897786 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 217
Study 2087821 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthraquinone containing laxative
Number of subjects: 22
Study 2087821 — intervention group
Group type: COMPARATOR
Intervention: Control (no anthraquinone laxative)
Number of subjects: 22
Study 358472 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 62
Study 358472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31580714 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 469
Study 31580714 — intervention group
Group type: COMPARATOR
Intervention: Western Medicine (WM)
Number of subjects: 469
Study 28641875 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay mesh reinforcement
Number of subjects: 480
Study 28641875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublay mesh reinforcement
Number of subjects: 480
Study 28641875 — intervention group
Group type: COMPARATOR
Intervention: Primary suture only
Number of subjects: 480
Study 28641875 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 480
Study 25644096 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide foam 2 mg/25 mL twice daily for 2 weeks, then once daily for 4 weeks
Number of subjects: 546
Study 23597323 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-instruction
Number of subjects: 261
Study 23597323 — intervention group
Group type: COMPARATOR
Intervention: Wait list (Control)
Number of subjects: 261
Study 21714792 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) pacing
Number of subjects: 21
Study 21714792 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricle (LV) pacing
Number of subjects: 21
Study 21714792 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 21
Study 19147636 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically informed sessions by trained health visitors for one hour a week for eight weeks.
Number of subjects: 4084
Study 19147636 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by health visitors in the control group.
Number of subjects: 4084
Study 16987710 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 68
Study 16987710 — intervention group
Group type: COMPARATOR
Intervention: No antiretroviral therapy
Number of subjects: 68
Study 12631652 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (acute administration for 24 hours)
Number of subjects: 43
Study 12631652 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (chronic administration for four weeks, 10 mg four times daily)
Number of subjects: 43
Study 12631652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acute administration for 24 hours)
Number of subjects: 43
Study 12631652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chronic administration for four weeks)
Number of subjects: 43
Study 10691866 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐CdA + prednisone
Number of subjects: 378
Study 10691866 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐CdA alone
Number of subjects: 378
Study 10691866 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐CdA
Number of subjects: 378
Study 10691866 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections and fever of unknown origin
Number of subjects: 378
Study 9360661 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intravenous iron once weekly
Number of subjects: 17
Study 9360661 — intervention group
Group type: COMPARATOR
Intervention: 50 mg intravenous iron twice weekly
Number of subjects: 17
Study 7505159 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed written information about maternal‐serum alpha‐fetoprotein testing
Number of subjects: 85
Study 7505159 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety management training
Number of subjects: 85
Study 7505159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of detailed written information and anxiety management training
Number of subjects: 85
Study 7505159 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of study questionnaires
Number of subjects: 85
Study 7505159 — intervention group
Group type: COMPARATOR
Intervention: Receipt of abnormal alpha‐fetoprotein result
Number of subjects: 85
Study 3544665 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic cup of Kobayashi
Number of subjects: 100
Study 3544665 — intervention group
Group type: COMPARATOR
Intervention: Malmström extractor
Number of subjects: 100
Study 30339891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D group)
Number of subjects: 102
Study 30339891 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (M group)
Number of subjects: 102
Study 30016743 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare Dad2K
Number of subjects: 99
Study 30016743 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (receiving parenting information in the mail)
Number of subjects: 99
Study 26847970 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-servo ventilation (ASV)
Number of subjects: 63
Study 26847970 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment alone (control)
Number of subjects: 63
Study 23446198 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (specific medication not mentioned)
Number of subjects: 439
Study 22891225 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal-focused anticipatory guidance (MOMS)
Number of subjects: 292
Study 22891225 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-focused anticipatory guidance (Ounce of Prevention)
Number of subjects: 292
Study 22891225 — intervention group
Group type: COMPARATOR
Intervention: Routine advice (Bright Futures)
Number of subjects: 292
Study 20606083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg once daily)
Number of subjects: 230
Study 20606083 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib (1,500 mg once daily)
Number of subjects: 230
Study 20606083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus Pazopanib (1,000 mg plus 400 mg once daily or 1,500 mg plus 800 mg once daily)
Number of subjects: 230
Study 17209214 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation
Number of subjects: 0
Study 15867239 — intervention group
Group type: EXPERIMENTAL
Intervention: 17AAG (10 to 395 mg/m2)
Number of subjects: 45
Study 15867239 — intervention group
Group type: EXPERIMENTAL
Intervention: 17AAG (10 to 295 mg/m2)
Number of subjects: 45
Study 12362100 — intervention group
Group type: EXPERIMENTAL
Intervention: EUBT with 100 mg of (13)C-urea
Number of subjects: 325
Study 12362100 — intervention group
Group type: EXPERIMENTAL
Intervention: EUBT with 50 mg of (13)C-urea
Number of subjects: 325
Study 12362100 — intervention group
Group type: EXPERIMENTAL
Intervention: EUBT with 25 mg of (13)C-urea
Number of subjects: 325
Study 10466665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 116
Study 10466665 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli (Nissle 1917)
Number of subjects: 116
Study 7838898 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam therapy (2-2.5 mg for 30 days)
Number of subjects: 10
Study 7838898 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 psychophysically healthy controls)
Number of subjects: 10
Study 7838898 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH stimulation (1 microgram/kg b.w.)
Number of subjects: 10
Study 7838898 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine stimulation (150 micrograms)
Number of subjects: 10
Study 1707298 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (75, 150, 300, or 600 micrograms protein/day, administered SC twice a day for 5 days)
Number of subjects: 11
Study 1707298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 477008 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective shunt
Number of subjects: 0
Study 477008 — intervention group
Group type: EXPERIMENTAL
Intervention: Total shunt
Number of subjects: 0
Study 477008 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31939363 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + Photodynamic therapy (using Indocyanine green)
Number of subjects: 30
Study 31939363 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 30
Study 28075507 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour at 39 weeks
Number of subjects: 0
Study 25998923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors
Number of subjects: 245283
Study 23715630 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg once daily
Number of subjects: 298
Study 23715630 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg once daily
Number of subjects: 298
Study 20657034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 750
Study 20657034 — intervention group
Group type: COMPARATOR
Intervention: Interferon-α (IFN-α)
Number of subjects: 750
Study 19583878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (50 g daily dose with 70% cocoa containing 750 mg polyphenols)
Number of subjects: 36
Study 19583878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato extract (one capsule containing 15 mg lycopene per day)
Number of subjects: 36
Study 19583878 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule daily)
Number of subjects: 36
Study 17299503 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 18
Study 17299503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15494087 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing PTSD coping skills group
Number of subjects: 20
Study 15494087 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face PTSD coping skills group
Number of subjects: 20
Study 11284758 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Ketorolac trometamol 0.5% ophthalmic solution
Number of subjects: 88
Study 11284758 — intervention group
Group type: COMPARATOR
Intervention: Placebo Liquifilm tears
Number of subjects: 88
Study 9210073 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled weighing
Number of subjects: 14
Study 9210073 — intervention group
Group type: COMPARATOR
Intervention: Unsaddled weighing
Number of subjects: 14
Study 8190431 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict control (n=68): fasting blood glucose < 4.44 mmol/L and postprandial blood glucose < 6.66 mmol/L
Number of subjects: 137
Study 8190431 — intervention group
Group type: COMPARATOR
Intervention: Customary control (n=69): fasting blood glucose < 5.55 mmol/L and postprandial blood glucose < 7.77 mmol/L
Number of subjects: 137
Study 3110944 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 120
Study 3110944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (SATM)
Number of subjects: 120
Study 30476251 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (starting dose 80 mg PO daily)
Number of subjects: 80
Study 30476251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28345432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate, 50 mg
Number of subjects: 54
Study 28345432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26878553 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week structured exercise with a jaw mobilizing device (TheraBite® jaw device or Engström device)
Number of subjects: 50
Study 26878553 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 24865782 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaclear high‐flux (A)
Number of subjects: 25
Study 24865782 — intervention group
Group type: EXPERIMENTAL
Intervention: Helixone high‐flux (B)
Number of subjects: 25
Study 24865782 — intervention group
Group type: EXPERIMENTAL
Intervention: Xevonta high‐flux (C)
Number of subjects: 25
Study 24865782 — intervention group
Group type: EXPERIMENTAL
Intervention: Helixone low‐flux (D)
Number of subjects: 25
Study 22311531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin plus risperidone
Number of subjects: 109
Study 22311531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (risperidone only)
Number of subjects: 109
Study 20442354 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg orally daily
Number of subjects: 0
Study 20442354 — intervention group
Group type: COMPARATOR
Intervention: Topical minoxidil
Number of subjects: 0
Study 17850539 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term prevention regimens for menstrual migraine
Number of subjects: 0
Study 15857519 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia Pneumoniae positive group (aCP‐IgG > 1:8)
Number of subjects: 16
Study 15857519 — intervention group
Group type: COMPARATOR
Intervention: Control group (aCP‐IgG <or= 1:8)
Number of subjects: 16
Study 15857519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CP positive and CTRL)
Number of subjects: 16
Study 12450262 — intervention group
Group type: EXPERIMENTAL
Intervention: LQT1 patients (n = 7)
Number of subjects: 49
Study 12450262 — intervention group
Group type: EXPERIMENTAL
Intervention: LQT2 patients (n = 9)
Number of subjects: 49
Study 12450262 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 49
Study 9933794 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day of urapidil for 4 weeks
Number of subjects: 149
Study 9933794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 9933794 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 149
Study 7569017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple fractions per day (MFD) with misonidazole
Number of subjects: 523
Study 7569017 — intervention group
Group type: COMPARATOR
Intervention: Multiple fractions per day (MFD) without misonidazole
Number of subjects: 523
Study 7569017 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 523
Study 2179912 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vacuum suction (VariDyne)
Number of subjects: 126
Study 2179912 — intervention group
Group type: COMPARATOR
Intervention: Intermittent spring type system (Hemovac)
Number of subjects: 126
Study 157264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel
Number of subjects: 0
Study 157264 — intervention group
Group type: COMPARATOR
Intervention: 0.05% retinoic acid cream
Number of subjects: 0
Study 30528795 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuchi‐kara Taberu (KT) index intervention
Number of subjects: 233
Study 30528795 — intervention group
Group type: COMPARATOR
Intervention: Control group (before KT index intervention)
Number of subjects: 233
Study 28218343 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic‐assisted gait training
Number of subjects: 16
Study 28218343 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 16
Study 25387428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation applied to the trapezius muscle
Number of subjects: 100
Study 25387428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 25123060 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-O (2.4 g/day DHA and EPA in a 2.7:1 ratio)
Number of subjects: 93
Study 25123060 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO; 2.0 g/day DHA and EPA in a 0.7:1 ratio)
Number of subjects: 93
Study 25123060 — intervention group
Group type: COMPARATOR
Intervention: Corn oil/soy oil control
Number of subjects: 93
Study 25123060 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-O
Number of subjects: 93
Study 25123060 — intervention group
Group type: EXPERIMENTAL
Intervention: FO
Number of subjects: 93
Study 22825363 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy (CE)
Number of subjects: 60
Study 22825363 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 60
Study 19864409 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/d)
Number of subjects: 672
Study 19864409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 17377120 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dexamethasone IV
Number of subjects: 60
Study 17377120 — intervention group
Group type: COMPARATOR
Intervention: 2 mL saline
Number of subjects: 60
Study 14593453 — intervention group
Group type: EXPERIMENTAL
Intervention: DOEScore
Number of subjects: 1256
Study 14593453 — intervention group
Group type: COMPARATOR
Intervention: FOSTA, SOFSURF, ORAI score systems
Number of subjects: 1256
Study 11810130 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5/6
Number of subjects: 9
Study 11810130 — intervention group
Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 9
Study 9588451 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin response to a 75‐g oral glucose load in nonrelatives
Number of subjects: 88
Study 9588451 — intervention group
Group type: COMPARATOR
Intervention: Insulin response to a 75‐g oral glucose load in relatives
Number of subjects: 88
Study 9588451 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis for insulin response in nonrelatives
Number of subjects: 88
Study 9588451 — intervention group
Group type: COMPARATOR
Intervention: Multivariate analysis for insulin response in relatives
Number of subjects: 88
Study 7979639 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg LA
Number of subjects: 82
Study 7979639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 2609241 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (60 micrograms i.v. infusion daily for 3 weeks)
Number of subjects: 48
Study 2609241 — intervention group
Group type: COMPARATOR
Intervention: Naftidrofuryl (600 mg daily for 3 weeks)
Number of subjects: 48
Study 1098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate and phenylpropanolamine hydrochloride (Lunerin mite)
Number of subjects: 17
Study 1098353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31756536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem autologous transplant (auto-auto)
Number of subjects: 710
Study 31756536 — intervention group
Group type: COMPARATOR
Intervention: Autologous followed by reduced intensity allogeneic transplantation (auto-allo)
Number of subjects: 710
Study 31756536 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HCT
Number of subjects: 710
Study 27469294 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dental implants (6-8 mm)
Number of subjects: 87
Study 27469294 — intervention group
Group type: EXPERIMENTAL
Intervention: Long dental implants (11 mm)
Number of subjects: 87